Company Intends to Enter Clinic with OSE-172 in Oncology by End of 2018
Data presented at 15th Annual “Discovery on Target” Conference
NANTES, France I October 02, 2017 I OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) presented new ex vivo and preclinical data on its first-in-class checkpoint inhibitor OSE-172 targeting selectively SIRP-alpha, a target expressed on myeloid suppressive cells. The data were presented at the 15th Annual Discovery on Target Conference which took place September 25-29, 2017 in Boston, MA.
Key results from the studies indicated that OSE-172 significantly:
- Reversed in vivo tumor immuno-suppressive microenvironment and decreased tumor growth in a Triple Negative Breast Cancer (TNBC) model;
- Inhibited metastasis spread in a TNBC model;
- Synergized survival when combined with PD-1/ PD-L1 blockade in a HepatoCellular Carcinoma (HCC) model, reinforcing the rationale for combination treatment;
- Induced potent memory anti-tumor immune responses when combined;
- Reduced immunosuppressive myeloid cell function from human ovarian cancer ascites in an ex vivo model; and
- Bound selectively to SIRP-alpha but did not bind to SIRP-gamma, a human costimulatory receptor required for human T-cell responses.
“Myeloid suppressive cells are involved in the tumor microenvironment of various tumors impeding T-cytotoxic cells from being effective against tumor cells. Myeloid suppressive cells play a role in tumor growth, metastasis process and immune escape mechanisms,” said Bernard Vanhove, COO and Head of R&D and International Scientific Collaborations at OSE Immunotherapeutics. “We are very encouraged by the new OSE-172 human ex vivo and preclinical data, which support the development of this anti-SIRP-alpha antibody in monotherapy and in combination with PD‑1/PD‑L1 checkpoint inhibitors.”
Dominique Costantini, CEO of OSE Immunotherapeutics, added: “We congratulate all the OSE team for these demonstrative data reinforcing the rationale for OSE-172, our first-in-class myeloid checkpoint inhibitor and we look forward to beginning clinical trials in oncology by the end of 2018.”
ABOUT OSE Immunotherapeutics
Our ambition is to become a world leader in activation and regulation immunotherapies:
OSE Immunotherapeutics is a biotechnology company focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, autoimmune diseases and transplantation. The company has several scientific and technological platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases. Its first-in-class clinical portfolio offers a diversified risk profile.
In immuno-oncology:
- Tedopi®, 10 combined neo-epitopes to induce specific T activation in immuno-oncology – Phase 3 trial in advanced NSCLC; follow-up of patients included ongoing after temporary pause of new patient accrual end of June 2017.
Phase 2 with Tedopi® in combination with an immune checkpoint inhibitor planned in advanced pancreatic cancer, in collaboration with GERCOR, a cooperative group of clinical research.
- OSE-172 (Effi-DEM), new generation checkpoint inhibitor targeting myeloid cells via the SIRP-α receptor – In preclinical development for several cancer models. Clinical program planned end of 2018.
- OSE-703 (Effi-3), cytotoxic monoclonal antibody against the alpha chain of IL-7R – Under a research collaboration with Memorial Sloan Kettering Cancer Center, New York.
In auto-immune diseases and transplantation:
- FR104, CD28-antagonist in immunotherapy – Phase 1 trial completed – For the treatment of autoimmune diseases and for use with transplantation – Licensed to Janssen Biotech Inc. to pursue clinical development. Phase 2 planned end of 2018 in rheumatoid arthritis.
- OSE-127 (Effi-7), interleukin receptor-7 antagonist – In preclinical development for inflammatory bowel diseases and other autoimmune diseases. Clinical phase planned end of 2018. License option agreement with Servier for the development and commercialization.
The portfolio’s blockbuster potential gives OSE Immunotherapeutics the ability to enter global agreements at different stages of development with major pharmaceutical players.
Immunotherapy is a highly promising and growing market. By 2023 Immunotherapy of cancer could represent nearly 60% of treatments against less than 3% at present * and the projected market is estimated at $67 billion in 2018 **. There are more than 80 autoimmune diseases that represent a significant market including major players in the pharmaceutical industry with sales towards $10 billion for the main products. The medical need is largely unmet and requires the provision of new innovative products involved in the regulation of the immune system.
SOURCE: OSE Immunotherapeutics
Post Views: 34
Company Intends to Enter Clinic with OSE-172 in Oncology by End of 2018
Data presented at 15th Annual “Discovery on Target” Conference
NANTES, France I October 02, 2017 I OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) presented new ex vivo and preclinical data on its first-in-class checkpoint inhibitor OSE-172 targeting selectively SIRP-alpha, a target expressed on myeloid suppressive cells. The data were presented at the 15th Annual Discovery on Target Conference which took place September 25-29, 2017 in Boston, MA.
Key results from the studies indicated that OSE-172 significantly:
- Reversed in vivo tumor immuno-suppressive microenvironment and decreased tumor growth in a Triple Negative Breast Cancer (TNBC) model;
- Inhibited metastasis spread in a TNBC model;
- Synergized survival when combined with PD-1/ PD-L1 blockade in a HepatoCellular Carcinoma (HCC) model, reinforcing the rationale for combination treatment;
- Induced potent memory anti-tumor immune responses when combined;
- Reduced immunosuppressive myeloid cell function from human ovarian cancer ascites in an ex vivo model; and
- Bound selectively to SIRP-alpha but did not bind to SIRP-gamma, a human costimulatory receptor required for human T-cell responses.
“Myeloid suppressive cells are involved in the tumor microenvironment of various tumors impeding T-cytotoxic cells from being effective against tumor cells. Myeloid suppressive cells play a role in tumor growth, metastasis process and immune escape mechanisms,” said Bernard Vanhove, COO and Head of R&D and International Scientific Collaborations at OSE Immunotherapeutics. “We are very encouraged by the new OSE-172 human ex vivo and preclinical data, which support the development of this anti-SIRP-alpha antibody in monotherapy and in combination with PD‑1/PD‑L1 checkpoint inhibitors.”
Dominique Costantini, CEO of OSE Immunotherapeutics, added: “We congratulate all the OSE team for these demonstrative data reinforcing the rationale for OSE-172, our first-in-class myeloid checkpoint inhibitor and we look forward to beginning clinical trials in oncology by the end of 2018.”
ABOUT OSE Immunotherapeutics
Our ambition is to become a world leader in activation and regulation immunotherapies:
OSE Immunotherapeutics is a biotechnology company focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, autoimmune diseases and transplantation. The company has several scientific and technological platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases. Its first-in-class clinical portfolio offers a diversified risk profile.
In immuno-oncology:
- Tedopi®, 10 combined neo-epitopes to induce specific T activation in immuno-oncology – Phase 3 trial in advanced NSCLC; follow-up of patients included ongoing after temporary pause of new patient accrual end of June 2017.
Phase 2 with Tedopi® in combination with an immune checkpoint inhibitor planned in advanced pancreatic cancer, in collaboration with GERCOR, a cooperative group of clinical research.
- OSE-172 (Effi-DEM), new generation checkpoint inhibitor targeting myeloid cells via the SIRP-α receptor – In preclinical development for several cancer models. Clinical program planned end of 2018.
- OSE-703 (Effi-3), cytotoxic monoclonal antibody against the alpha chain of IL-7R – Under a research collaboration with Memorial Sloan Kettering Cancer Center, New York.
In auto-immune diseases and transplantation:
- FR104, CD28-antagonist in immunotherapy – Phase 1 trial completed – For the treatment of autoimmune diseases and for use with transplantation – Licensed to Janssen Biotech Inc. to pursue clinical development. Phase 2 planned end of 2018 in rheumatoid arthritis.
- OSE-127 (Effi-7), interleukin receptor-7 antagonist – In preclinical development for inflammatory bowel diseases and other autoimmune diseases. Clinical phase planned end of 2018. License option agreement with Servier for the development and commercialization.
The portfolio’s blockbuster potential gives OSE Immunotherapeutics the ability to enter global agreements at different stages of development with major pharmaceutical players.
Immunotherapy is a highly promising and growing market. By 2023 Immunotherapy of cancer could represent nearly 60% of treatments against less than 3% at present * and the projected market is estimated at $67 billion in 2018 **. There are more than 80 autoimmune diseases that represent a significant market including major players in the pharmaceutical industry with sales towards $10 billion for the main products. The medical need is largely unmet and requires the provision of new innovative products involved in the regulation of the immune system.
SOURCE: OSE Immunotherapeutics
Post Views: 34
